Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin

Michele Columbo, Daniela Galeone, Guido Guidi, Anne Kagey-Sobotka, Lawrence M. Lichtenstein, George Pettit, Gianni Marone

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Auranofln, a new orally absorbable gold compound, inhibits IgE-(anti-IgE) and non-IgE-mediated (f-met-peptide and the Ca2+ ionophore A23187) histamine release from human basophils. Auranofin inhibits the release of histamine induced by phorbol myristate (TPA) and bryostatin 1 both in the presence and absence of extracellular Ca2+. Increasing the Ca2+ concentrations in the extracellular medium does not reduce the inhibitory effect of auranofin on anti-IgE- or A23187-induced secretion. Auranofin inhibits the de novo synthesis of sulfidopeptide leukotriene C4 (LTC4) induced by anti-IgE from basophils and mast cells purified from human lung. However, in both systems auranofin has a significantly greater inhibitory effect on LTC4 release than on histamine secretion. Finally, auranofin induces a concentration-dependent inhibition of A23187-induced leukotrine B4 (LTB4) release from purified human lung macrophages. These data suggest that auranofin modulates the release of preformed (histamine) and de novo synthesized (LTC4 and LTB4) chemical mediators from human inflammatory cells isolated from peripheral blood and human lung tissues.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalBiochemical Pharmacology
Issue number2
StatePublished - Jan 15 1990

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology


Dive into the research topics of 'Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin'. Together they form a unique fingerprint.

Cite this